Emcure net profit zooms 63% to Rs 197 crore in Q4FY25

Emcure

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Emcure Pharmaceuticals on Thursday reported 63 percent year-on-year (YoY) jump in its consolidated Profit After Tax (PAT) for the fourth quarter of fiscal year 2025, reaching Rs 197 crore led by strong performance across both its domestic and international business segments.

The profit growth was propelled by a 19.5 percent year-over-year rise in revenue from operations, which stood at Rs 2,116 crore for the quarter ended March 31, 2025. The company's EBITDA also saw a healthy increase of 25.2 percent year-over-year to Rs 390 crore, with EBITDA margins at 18.4 percent.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., commented on the results, stating, "Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth."

Domestic formulation sales grew by 24.8 percent YoY to Rs 929 crore, primarily fueled by strong performance in its women's health and cardio therapy segments. New focus areas such as dermatology and Over-the-Counter (OTC) products also contributed to this growth.

Emcure Pharma shares hit 10% upper circuit after Q4 net profit jumps 64%

The international segment recorded a 15.6 percent year-over-year growth in sales, reaching Rs 1,187 crore. This was significantly bolstered by a robust 39.3 percent growth in the rest of the world segment.

The company's Canada business, with Mantra fully integrated, continued its strong performance.
In Europe, recent product portfolio acquisitions and key regulatory approvals are expected to support future growth.

For the full fiscal year 2025, Emcure Pharmaceuticals reported a PAT of Rs 707 crore, representing a 34.1 percent increase compared to the previous year. Revenue from operations reached Rs 7,896 crore, up 18.6 percent YoY. EBITDA for the year grew by 17.5 perent to Rs 1,438 crore.

The Board of Directors has proposed a final dividend of Rs 3 per share.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.